Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder.

ABSTRACT:

Background

Identifying neuroimaging biomarkers of antidepressant response may help guide treatment decisions and advance precision medicine.

Aims

To examine the relationship between anhedonia and functional neurocircuitry in key reward processing brain regions in people with major depressive disorder receiving aripiprazole adjunct therapy with escitalopram.

Method

Data were collected as part of the CAN-BIND-1 study. Participants experiencing a current major depressive episode received escitalopram for 8 weeks; escitalopram non-responders received adjunct aripiprazole for an additional 8 weeks. Functional magnetic resonance imaging (on weeks 0 and 8) and clinical assessment of anhedonia (on weeks 0, 8 and 16) were completed. Seed-based correlational analysis was employ

SUBMITTER: Vaccarino SR 

PROVIDER: S-EPMC10790221 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature